GlassScriptPhysician profile
Ashlei Mathew
NPI 1730356015
$5,065.64
in general payments reported to CMS, 2019-2025
22 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.31 · 2020: $124 · 2021: $502 · 2022: $822 · 2023: $843 · 2024: $1,364 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,579.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,065.88 | 2019-2025 | Dupixent |
| Genzyme Corporation | $954.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $852.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $411.24 | 2021-2025 | Tezspire, Fasenra |
| Optinose US, INC. | $303.94 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $257.90 | 2024-2025 | |
| Alk-Abello, INC | $224.18 | 2020-2022 | |
| Kaleo, INC. | $149.85 | 2022-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $132.27 | 2024-2025 | Glassia, Cuvitru, Eohilia |
| Amgen INC. | $116.82 | 2022-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $106.37 | 2024-2025 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $105.75 | 2025 | Neffy |
| Grifols USA, LLC | $82.43 | 2023-2025 | Xembify |
| Pfizer INC. | $78.39 | 2020-2024 | |
| Biocryst US Sales Co., LLC | $70.25 | 2024 | Orladeyo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $29.90 | 2024 | Opzelura |
| Phadia US INC. | $25.60 | 2024 | Immunocap |
| Inspire Medical Systems, INC. | $25.20 | 2025 | Inspire |
| Pharming Healthcare, INC. | $22.62 | 2024 | Ruconest |
| Abbvie INC. | $19.50 | 2023 | |
| Merck Sharp & Dohme LLC | $15.68 | 2023 | |
| Neos Therapeutics, LP | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlei Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.